[go: up one dir, main page]

WO2010028079A3 - Procédés synthétiques et dérivés d’oligonucléotides triphosphates - Google Patents

Procédés synthétiques et dérivés d’oligonucléotides triphosphates Download PDF

Info

Publication number
WO2010028079A3
WO2010028079A3 PCT/US2009/055775 US2009055775W WO2010028079A3 WO 2010028079 A3 WO2010028079 A3 WO 2010028079A3 US 2009055775 W US2009055775 W US 2009055775W WO 2010028079 A3 WO2010028079 A3 WO 2010028079A3
Authority
WO
WIPO (PCT)
Prior art keywords
derivatives
synthetic methods
triphosphate
methods
infections
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/055775
Other languages
English (en)
Other versions
WO2010028079A2 (fr
Inventor
Muthiah Manoharan
Kallanthottathil G. Rajeev
Ivan Zlatev
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alnylam Pharmaceuticals Inc
Original Assignee
Alnylam Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alnylam Pharmaceuticals Inc filed Critical Alnylam Pharmaceuticals Inc
Priority to CA2735860A priority Critical patent/CA2735860A1/fr
Priority to JP2011526173A priority patent/JP2012502040A/ja
Priority to US13/061,736 priority patent/US20120107272A1/en
Priority to EP09792189A priority patent/EP2344514A2/fr
Priority to AU2009288078A priority patent/AU2009288078B2/en
Priority to PCT/US2009/069201 priority patent/WO2011028218A1/fr
Publication of WO2010028079A2 publication Critical patent/WO2010028079A2/fr
Publication of WO2010028079A3 publication Critical patent/WO2010028079A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention porte sur un oligonucléotide de formule (I) ou sur des sels pharmaceutiquement acceptables ou promédicaments de celui-ci : (I) qui sont capables d'induire une réponse antivirale ou une réponse antibactérienne, en particulier, l'induction d'IFN de type I, d’IL-18 et/ou d’IL-1β par liaison à RIG-1. L'invention porte sur des procédés de fabrication et d'utilisation de l'oligonucléotide modifié comprenant au moins un triphosphate ou des analogues de celui-ci. L'invention porte en outre sur des méthodes permettant de traiter divers troubles et diverses maladies, tels que des infections virales, des infections bactériennes, des infections parasitaires, des tumeurs, des allergies, des maladies auto-immunes, des immunodéficiences et des immunosuppressions.
PCT/US2009/055775 2008-09-02 2009-09-02 Procédés synthétiques et dérivés d’oligonucléotides triphosphates Ceased WO2010028079A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA2735860A CA2735860A1 (fr) 2008-09-02 2009-09-02 Procedes synthetiques et derives d'oligonucleotides triphosphates
JP2011526173A JP2012502040A (ja) 2008-09-02 2009-09-02 三リン酸塩オリゴヌクレオチドの合成方法および誘導体
US13/061,736 US20120107272A1 (en) 2008-09-02 2009-09-02 Synthetic methods and derivatives of triphosphate oligonucleotides
EP09792189A EP2344514A2 (fr) 2008-09-02 2009-09-02 Procédés synthétiques et dérivés d'oligonucléotides triphosphates
AU2009288078A AU2009288078B2 (en) 2008-09-02 2009-09-02 Synthetic methods and derivatives of triphosphate oligonucleotides
PCT/US2009/069201 WO2011028218A1 (fr) 2009-09-02 2009-12-22 Procédé pour la synthèse d'oligonucléotides triphosphates

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9364208P 2008-09-02 2008-09-02
US61/093,642 2008-09-02

Publications (2)

Publication Number Publication Date
WO2010028079A2 WO2010028079A2 (fr) 2010-03-11
WO2010028079A3 true WO2010028079A3 (fr) 2010-06-17

Family

ID=41797835

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/055775 Ceased WO2010028079A2 (fr) 2008-09-02 2009-09-02 Procédés synthétiques et dérivés d’oligonucléotides triphosphates

Country Status (6)

Country Link
US (2) US20120107272A1 (fr)
EP (1) EP2344514A2 (fr)
JP (1) JP2012502040A (fr)
AU (1) AU2009288078B2 (fr)
CA (1) CA2735860A1 (fr)
WO (1) WO2010028079A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2056845T1 (en) 2006-08-08 2018-02-28 Rheinische Friedrich-Wilhelms-Universitaet Bonn STRUCTURE AND USE 5 'PHOSPHATE OF OLIGONUCLEOTES
JP5689413B2 (ja) 2008-05-21 2015-03-25 ライニッシュ フリードリッヒ−ウィルヘルムズ−ユニバーシタット ボン 平滑末端を有する５’三リン酸オリゴヌクレオチドおよびその使用
JP2012502040A (ja) * 2008-09-02 2012-01-26 アルニラム ファーマスーティカルズ インコーポレイテッド 三リン酸塩オリゴヌクレオチドの合成方法および誘導体
KR101261589B1 (ko) 2010-04-09 2013-05-06 주식회사 포스코 Ｒｉｇ－ｉ 단백질을 표적으로 하는 ｒｎａ 앱타머 및 그의 용도
JP6106085B2 (ja) * 2010-08-24 2017-03-29 サーナ・セラピューティクス・インコーポレイテッドＳｉｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 内部非核酸スペーサーを含む一本鎖ＲＮＡｉ剤
EP2508530A1 (fr) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification d'oligonucléotides triphosphorylés au moyen d'étiquettes de capture
EP2712870A1 (fr) * 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Nouveaux ligands de RIG-I et procédés pour les produire
WO2014124433A1 (fr) * 2013-02-11 2014-08-14 Oregon Health & Science University Oligoribonucléotides 5'-triphosphate
US10947543B2 (en) 2013-03-13 2021-03-16 Yale University Interferon production using short RNA duplexes
WO2014169049A1 (fr) * 2013-04-09 2014-10-16 Duke University Arn 2'fluoro-modifiés en tant qu'immunostimulateurs
US10174328B2 (en) * 2013-10-04 2019-01-08 Translate Bio Ma, Inc. Compositions and methods for treating amyotrophic lateral sclerosis
US10059940B2 (en) * 2015-01-27 2018-08-28 Minghong Zhong Chemically ligated RNAs for CRISPR/Cas9-lgRNA complexes as antiviral therapeutic agents
DE102015008536A1 (de) * 2015-07-02 2017-01-05 Rheinische Friedrich-Wilhelms-Universität Bonn Diskontinuierliche Oligonukleotid-Liganden
US11613756B2 (en) 2017-04-03 2023-03-28 Duke University Compositions and methods for differential induction of cell death and interferon expression
US10907161B2 (en) 2018-04-19 2021-02-02 Checkmate Pharmaceuticals, Inc. Synthetic RIG-I-like receptor agonists
SE546008C2 (en) * 2021-09-16 2024-04-09 Peptisystems Ab Processes and systems for flow-through oligonucleotide synthesis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050119214A1 (en) * 2003-04-17 2005-06-02 Muthiah Manoharan Nuclease resistant double-stranded ribonucleic acid

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2828642B2 (ja) * 1987-06-24 1998-11-25 ハワード フローレイ インスティテュト オブ イクスペリメンタル フィジオロジー アンド メディシン ヌクレオシド誘導体
US6174998B1 (en) * 1996-03-12 2001-01-16 Roche Diagnostics Gmbh C-nucleoside derivatives and their use in the detection of nucleic acids
FR2793988B1 (fr) * 1999-05-19 2003-01-31 Matra Nortel Communications Procede de radiocommunication entre une station de base et des terminaux mobiles, stations de base et terminaux mobiles pour la mise en oeuvre d'un tel procede
JP2003508063A (ja) * 1999-09-01 2003-03-04 イェダ リサーチ アンド デベロップメント カンパニー リミテッド オリゴヌクレオチド三リン酸構築ブロックを用いた鋳型依存核酸重合化
CA2562685C (fr) * 2004-04-27 2013-09-17 Alnylam Pharmaceuticals, Inc. Oligonucleotides mono-brin et double brin a fraction 2-arylpropyle
AU2005327517B2 (en) * 2004-06-30 2011-05-26 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a non-phosphate backbone linkage
AU2005328382C1 (en) * 2004-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a modified or non-natural nucleobase
US7759469B2 (en) * 2005-03-10 2010-07-20 Roche Diagnostics Operations, Inc. Labeling reagent
US20110250138A1 (en) * 2007-08-01 2011-10-13 Alnylam Pharmaceuticals, Inc. Single-stranded and double-stranded oligonucleotides comprising a metal-chelating ligand
JP5689413B2 (ja) * 2008-05-21 2015-03-25 ライニッシュ フリードリッヒ−ウィルヘルムズ−ユニバーシタット ボン 平滑末端を有する５’三リン酸オリゴヌクレオチドおよびその使用
JP2012502040A (ja) * 2008-09-02 2012-01-26 アルニラム ファーマスーティカルズ インコーポレイテッド 三リン酸塩オリゴヌクレオチドの合成方法および誘導体
WO2011028218A1 (fr) 2009-09-02 2011-03-10 Alnylam Pharmaceuticals, Inc. Procédé pour la synthèse d'oligonucléotides triphosphates
US20110282044A1 (en) * 2009-12-22 2011-11-17 Alnylam Pharmaceuticals Process for synthesizing oligonucleotide phosphate derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050119214A1 (en) * 2003-04-17 2005-06-02 Muthiah Manoharan Nuclease resistant double-stranded ribonucleic acid

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A.F.COOK ET AL.: "Nucleoside S-alkyl phosphorothioates. III. Application to oligonucleotide synthesis", J. AM. CHEM. SOC., vol. 91, no. 23, 1 January 1969 (1969-01-01), pages 6479 - 6484, XP002577204 *
LEBEDEV A V ET AL: "PREPARATION OF OLIGODEOXYNUCLEOTIDE 5'-TRIPHOSPHATES USING SOLID SUPPORT APPROACH", NUCLEOSIDES, NUCLEOTIDES AND NUCLEIC ACIDS, TAYLOR & FRANCIS, PHILADELPHIA, PA LNKD- DOI:10.1081/NCN-100002565, vol. 20, no. 4-7, 1 January 2001 (2001-01-01), pages 1403 - 1409, XP009081703, ISSN: 1525-7770 *

Also Published As

Publication number Publication date
CA2735860A1 (fr) 2010-03-11
US9035041B2 (en) 2015-05-19
US20120107272A1 (en) 2012-05-03
WO2010028079A2 (fr) 2010-03-11
US20120220761A1 (en) 2012-08-30
JP2012502040A (ja) 2012-01-26
EP2344514A2 (fr) 2011-07-20
AU2009288078B2 (en) 2014-10-30
AU2009288078A1 (en) 2010-03-11

Similar Documents

Publication Publication Date Title
WO2010028079A3 (fr) Procédés synthétiques et dérivés d’oligonucléotides triphosphates
WO2011100131A3 (fr) Monomères et oligonucléotides comprenant un ou plusieurs adduits de cycloaddition
WO2012142093A3 (fr) Dérivés nucléosides à substitution 2'-cyano et leurs procédés d'utilisation pour traitement de maladies virales
WO2010151799A3 (fr) Composés de modulation des protéines de liaison à l'arn et applications associées
HK1203513A1 (en) Methods of preparing substituted nucleotide analogs
WO2008017473A3 (fr) Structure et utilisation d'oligonucléotides 5'-phosphate
WO2010151797A3 (fr) Composés de modulation des protéines de liaison à l'arn et applications associées
MD4403B1 (ro) Compuşi antivirali în bază de dihidroxiizocromen-naftoimidazoli condensaţi
IN2015DN02238A (fr)
NZ607996A (en) Substituted nucleotide analogs
EA201170915A1 (ru) Фосфорамидатные производные гуанозиновых нуклеозидов для лечения вирусных инфекций
WO2009111653A3 (fr) Agents thérapeutiques antiviraux
HK1216535A1 (zh) 取代的核苷、核苷酸及其類似物
BRPI0512683A (pt) compostos anti-virais
BR112012006858A2 (pt) metodo de aperfeicoamento do desempenho de impressao em placas de impressao flexografica
WO2008118332A3 (fr) Peptides hydrazido en tant qu'inhibiteurs de la protéase ns3 du hcv
CU20110083A7 (es) Compuestos heteroaromáticos espirocíclicos fusionados para el tratamiento de infecciones bacterianas
AU2012358805A8 (en) Pyrazolo[1,5-a]pyrimidines as antiviral agents
PH12015500211A1 (en) 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
WO2012125926A3 (fr) Dérivés tétracycliques de xanthène et leurs méthodes d'utilisation en vue du traitement de maladies virales
WO2010039548A3 (fr) Modifications chimiques de monomères et d'oligonucléotides par cycloaddition
WO2008121634A3 (fr) Promédicaments de phosphoramidate de nucléoside
EP2647644A4 (fr) Arn modifié par 2'-o
WO2014152965A3 (fr) Loci génétiques associés à la schizophrénie identifiés dans des études d'association sur génome total et leur utilisation en tant que nouvelles cibles thérapeutiques
WO2011057262A3 (fr) Traitement des infections par des antagonistes du récepteur tp

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09792189

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2735860

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2011526173

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009288078

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2009288078

Country of ref document: AU

Date of ref document: 20090902

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2009792189

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 13061736

Country of ref document: US